Journal
ENT-EAR NOSE & THROAT JOURNAL
Volume 100, Issue 9, Pages NP402-NP406Publisher
SAGE PUBLICATIONS INC
DOI: 10.1177/0145561320923170
Keywords
lymphoepithelial carcinoma; salivary gland tumors; induction chemotherapy; concurrent chemoradiotherapy
Categories
Ask authors/readers for more resources
This report describes 3 cases of advanced stage Lymphoepithelial carcinoma of the salivary gland treated with induction chemotherapy and concurrent chemoradiotherapy, all achieving complete response and remaining local-regional recurrence-free during follow-up. No serious adverse events were found.
Lymphoepithelial carcinoma (LEC) of the salivary gland is a rare malignancy which is identical to undifferentiated nasopharyngeal carcinoma. However, most patients are treated with surgery as primary treatment, which is impossible for some very locoregionally advanced patients. And there are few reports of patients treated by an induction chemotherapy (IC) and concurrent chemoradiotherapy (CCRT) approach. This report describes 3 cases of advanced stage LEC of the salivary gland. All patients presented with a palpable mass of variable duration and underwent induction CCRT. All cases were positive for Epstein-Barr virus-encoded small RNAs. After IC, all cases had reached partial response and all achieved complete response after CCRT. All patients remained local-regional recurrence-free after 6-month follow-up for case 1, 50-month for case 2, and 14-month for case 3 up to our last follow-up. No serious adverse events were found.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available